Next Article in Journal
Troponin Elevation in Older Patients with Acute Pneumonia: Frequency and Prognostic Value
Next Article in Special Issue
Best Procedure for the Management of Common Bile Duct Stones via the Papilla: Literature Review and Analysis of Procedural Efficacy and Safety
Previous Article in Journal
The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome
Previous Article in Special Issue
Which Are the Most Suitable Stents for Interventional Endoscopic Ultrasound?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 11
10.3390/jcm9113622
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Systematic Review with Meta-Analysis: Endoscopic and Surgical Resection for Ampullary Lesions

by
Christian Heise
1,†,
Einas Abou Ali
2,†,
Dirk Hasenclever
3,
Francesco Auriemma
4,
Aiste Gulla
5,6,
Sara Regner
7,
Sébastien Gaujoux
8 and
Marcus Hollenbach
9,*
1
Department of Medicine I—Gastroenterology, Pulmonology, Martin-Luther University Halle-Wittenberg, 06097 Halle, Germany
2
Department of Gastroenterology, Digestive Oncology and Endoscopy, Cochin Hospital, Paris Descartes University, 75014 Paris, France
3
Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, 04103 Leipzig, Germany
4
Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Clinical and Research Hospital, Rozzano, 20089 Milan, Italy
5
Department of Abdominal Surgery, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, 01513 Vilnius, Lithuania
6
General Surgery, MedStar Georgetown University Hospital, Washington, DC 20007, USA
7
Department of Clinical Sciences Malmö, Section for Surgery, Lund University, 221 00 Lund, Sweden
8
Department of Pancreatic and Endocrine Surgery, Pitié-Salpetriere Hospital, Médecine Sorbonne Université, 75000 Paris, France
9
Medical Department II, Division of Gastroenterology, University of Leipzig Medical Center, 04103 Leipzig, Germany
*
Author to whom correspondence should be addressed.
†
Authors contributed equally and shared first authorship.
J. Clin. Med. 2020, 9(11), 3622; https://doi.org/10.3390/jcm9113622
Submission received: 11 October 2020 / Revised: 30 October 2020 / Accepted: 30 October 2020 / Published: 10 November 2020
(This article belongs to the Special Issue Pancreato-Biliary Interventional Endoscopy)
Browse Figures
Versions Notes

Abstract

:
Ampullary lesions (ALs) can be treated by endoscopic (EA) or surgical ampullectomy (SA) or pancreaticoduodenectomy (PD). However, EA carries significant risk of incomplete resection while surgical interventions can lead to substantial morbidity. We performed a systematic review and meta-analysis for R0, adverse-events (AEs) and recurrence between EA, SA and PD. Electronic databases were searched from 1990 to 2018. Outcomes were calculated as pooled means using fixed and random-effects models and the Freeman-Tukey-Double-Arcsine-Proportion-model. We identified 59 independent studies. The pooled R0 rate was 76.6% (71.8–81.4%, I2 = 91.38%) for EA, 96.4% (93.6–99.2%, I2 = 37.8%) for SA and 98.9% (98.0–99.7%, I2 = 0%) for PD. AEs were 24.7% (19.8–29.6%, I2 = 86.4%), 28.3% (19.0–37.7%, I2 = 76.8%) and 44.7% (37.9–51.4%, I2 = 0%), respectively. Recurrences were registered in 13.0% (10.2–15.6%, I2 = 91.3%), 9.4% (4.8–14%, I2 = 57.3%) and 14.2% (9.5–18.9%, I2 = 0%). Differences between proportions were significant in R0 for EA compared to SA (p = 0.007) and PD (p = 0.022). AEs were statistically different only between EA and PD (p = 0.049) and recurrence showed no significance for EA/SA or EA/PD. Our data indicate an increased rate of complete resection in surgical interventions accompanied with a higher risk of complications. However, studies showed various sources of bias, limited quality of data and a significant heterogeneity, particularly in EA studies.

1. Introduction

Ampullary lesions (AL) are rare conditions and comprise 7 to 10% of periampullary lesions [1]. However, the incidence of ALs has clearly increased from 1973 to 2005 particularly in patients over the age of 50 [2]. Nowadays, most ALs are incidentally diagnosed by endoscopy or radiology imaging. However, in symptomatic patients, painless jaundice and cholangitis, acute pancreatitis, nausea, vomiting or weight loss have been described [3]. Most ALs are ampullary adenomas (AA) and adenocarcinomas (AC) following an adenoma-to-carcinoma sequence [4]. Some other rare entities such as neuroendocrine or mesenchymal lesions have also been described [5].
Treatment of ALs is historically a surgical approach but advances in endoscopic techniques have facilitated minimally invasive therapies [6]. Non-invasive ALs, carcinoma in situ and T1-node-negative adenocarcinoma can be treated either by endoscopic ampullectomy or papillectomy (EA) [7], surgical or trans-duodenal ampullectomy (SA) [8] or pancreaticoduodenectomy (PD) [9]. However, clear consensus guidelines or recommendations are lacking and the therapeutic strategy for ALs depends on local expertise. EA is usually performed for smaller lesions without any sign of invasive carcinoma, clear margins, soft tissue and absence of ulceration [10]. In contrast, recent studies describe the feasibility of “piece-meal” EA [11], even in large laterally spreading lesions, with deep ductal invasion [12] and supposed node-negative T1 adenocarcinoma [13]. Additionally, EA could be used as a “macrobiopsy” for tumor staging and as a bridge to surgery [14]. This is important, as recent studies still show limited pre-interventional accuracy of the endoscopic biopsy despite the use of EUS [15]. In addition, the significant morbidity and mortality of PD, as well as a notable recurrence of up to 43% in EA, have to be considered in the therapeutic decision for resection of ALs [16].
To date, randomized controlled trials that have matched EA and SA or PD directly are lacking. Only a few studies retrospectively compared endoscopic and surgical techniques for the treatment of ALs. These works revealed different inclusion criteria, outcomes and surgical approaches. In addition, the conclusions drawn were, at least in part, counterintuitive [11,16,17]. Thus, the aim of this systematic review and meta-analysis was to analyze the outcomes of EA, SA and PD for non-invasive ALs, carcinoma in situ and T1-node-negative adenocarcinoma in terms of complete resection (R0), complications and recurrences.

2. Methods

2.1. Data Sources

Our search strategy and inclusion criteria were based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations [18]. The analysis was registered in the PROSPERO-Database (on 19 August 2019, registration number 147795). We performed a systematic literature reveiw in Medline, EMBASE and SCOPUS on 27 September 2018 to identify studies that analyzed endoscopic or surgical interventions for ALs. Additionally we performed a manual research of references from representative articles and reviews.

2.2. Study Selection Process and Outcome Measures

Only human subject studies were considered in the analysis. Any retrospective or prospective study analyzing EA, SA or PD for ALs that reported at least one of the outcomes was included. The primary outcome measurement of our study was the rate of complete resection (R0) determined by histology. Secondary outcomes were overall complications (AEs) for endoscopic and surgical interventions and rate of recurrence. Recurrence was defined as a new lesion on endoscopy after initial negative follow-up endoscopy (in EA and SA) or local or distant recurrence in cross-sectional imaging (SA and PD). Further inclusion criteria were histologically proven ALs, patients >18 years, >10 patients per study, >90% ampullary adenoma or adenocarcinoma (T1 or carcinoma in situ), publication later than 1990. Studies were excluded, if they were deemed to have insufficient data or did not report independent data (e.g., review articles, editorials, correspondence letters, duplication and others) or did not fulfil inclusion criteria. A bibliography of full texts was established for all studies that could possibly meet inclusion criteria.

2.3. Quality Assessment

The data quality of the included studies was evaluated by the modified Newcastle–Ottawa Scale (NOS) (Table 1) for non-randomized studies, ranging from 0 (low-quality) to 9 (high-quality) [19]. The overall NOS-Score was calculated by 7 items (4 points for adequate selection, 2 for comparability and 3 for outcome). A study was scored as good quality if at least 3 points for selection, 1 for comparability and 2 for outcome were achieved. Fair quality was defined as 2 points for selection, 1 point for comparability or 1 point for outcome. Studies of poor quality reached 1 point for selection, no points for comparability or 1 point in outcome. All reviewers (CH, EAA, FA, AG, MH) assessed the specific quality indicators of the included publications.

2.4. Statistical Analysis

Statistical analyses were performed by means of openMeta[Analyst] (v. 12.11.14, http://www.cebm.brown.edu/openmeta/), “R” (version 3.5.3 distributed by www.r-project.org) and SPSS (version 25, IBM). We calculated pooled values for R0, complications and recurrence and presented the proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for analysis of EA and SA, as these studies showed high heterogeneity. In contrast, meta-analyses for PD were calculated by a fixed effect model with inverse variance weighting as data were of low heterogeneity. Statistical heterogeneity between the included studies was determined by forest plots and by calculating the I2 index. In the case of high heterogeneity, a sensitivity analysis was performed. All pooled event rates were shown in forest plots, regardless of the level of heterogeneity.
Studies were evaluated for publication bias by Egger’s test [20], and funnel plots were drawn by using JASP (v. 0.11.1, https://jasp-stats.org/). To compare endoscopic and surgical interventions, a proportion-meta-analysis was conducted. The individual study proportions were transformed into a quantity using the Freeman–Tukey Double Arcsine Proportion model. Then, the pooled proportion was calculated by transforming the weighted mean back out of the transformed proportions. For the transform, we used inverse arcsine variance weights for the fixed-effects model and DerSimonian–Laird weights for the random effects model [21]. Statistical significance was assessed by considering the 95% CIs of the two pooled proportions and the differences of proportions and their 95% CIs, respectively. All calculated p-values by Students t-test were 2-sided, and p < 0.05 was considered statistically significant. Combined weighted proportions were determined by use of the openMeta[Analyst].
Search strategy, screening and data extraction can be found in the supplemental material in methods.

3. Results

3.1. Study Characteristics and Quality

Our literature search revealed 2395 articles in total. Out of these, 1660 did not meet the topic. After screening of titles and abstracts, 367 studies remained. Finally, 59 papers were eligible to be included into the meta-analysis after full-text evaluation (42 EA, 8 SA, 1 PD, 3 SA + PD, 4 EA + SA, 1 EA + PD; Figure 1 PRISMA chart) [22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79]. We did not include conference abstracts that were not published as full-texts. Although some studies reported outcomes of different interventions, no single study directly compared different approaches with relevant patient count. Relevant study characteristics and quality assessment are reported in Table 2; Table 3. The majority of studies (n = 54, 92%) were retrospective single center reports. In total, out of the EA studies, we included 2658 patients (54.1% male) at an average age of 59.2 years for our analysis. Moreover, SA studies involved 393 patients (47.5% male) with a mean age of 63.5 years and PD studies involved 778 patients (53.3% male) with a mean age of 63.9 years. The follow-up after the procedures ranged between 5 and 190 months but was not adequately described in 18 studies (31%, Table 3).
The quality of the included articles was heterogeneous. Out of 59 papers, 35 were of good quality (59.4%) and 23 revealed poor scientific quality (38.9%) according to the NOS. One study was of fair quality (1.7%, all Table 2). Study quality was included in the sensitivity analysis.

3.2. Complete Resection in Endoscopic and Surgical Interventions

We were able to include 39 datasets of EA, 10 datasets of SA and 4 of PD in the meta-analysis for complete resection. Patients were asymptomatic in 54.4% (EA), 35.3% (SA) and 21.6% (PD). The mean lesion size of the different study cohorts was 19.7 mm (EA), 17.5 mm (SA) and 17.0 mm (PD). T1-adenocarcinoma and carcinoma-in-situ were found in 8.7% of patients in EA, in 30.8% in SA and in 100% of patients in PD (all Table 3). The remaining patients had non-invasive ALs. Thereby, a strict comparison, matching or propensity scoring was impossible to perform.
The pooled R0 rate was 76.6% (CI 71.8–81.4%) for EA (Figure 2A), 96.4% (CI 93.6–99.2%) for SA (Figure 2B) and 98.9% (CI 98.0–99.7%) for PD (Figure 2C). Nevertheless, published data of EA (I2 = 91.4%, p < 0.001) showed high heterogeneity compared to SA (I2 = 37.8%, p = 0.107) and PD (I2 = 0%, p = 0.531, all Figure 2). The proportion-meta-analysis resulted in transformed R0-rates of 77.3% (CI 71.7–82.5%, SE 0.032, I2 = 88.1%, p < 0.001) for EA, 94.6% (CI 89.1–98.4%, SE 0.045, I2 = 50.5%, p = 0.033) for SA and 99.2% (CI 98.1–99.9%, SE 0.020, I2 = 0%, p = 0.212) for PD. Calculations showed a significant difference for complete resection of EA compared to SA (p = 0.007) and EA compared to PD (p = 0.022).

3.3. Complications

Complications were assessed in 32 EA-datasets, 13 SA-datasets and 3 PD-datasets. As different types of complications were reported (Table 3), we conducted a meta-analysis to obtain a pooled estimate rate only for overall complications. Pooled overall complication rates were as follows: 24.7% (CI 19.8–29.6%) for EA (Figure 3A), 28.3% (CI 19.0–37.7%) for SA (Figure 3B) and 44.7% (CI 37.9–51.4%) for PD (Figure 3C). Heterogeneity was high in EA (I2 = 86.4%, p < 0.001) and SA (I2 = 76.8%, p < 0.001) but not PD (I2 = 0%, p = 0.653). The proportion-meta-analysis showed a pooled and transformed rate of complications of 24.5% (CI 19.8–29.4%, SE 0.027, I2 = 80.5, p < 0.001) for EA, 28.7% (CI 20.0–38.2%, SE 0.049, I2 = 66.5%, p < 0.001) for SA and 44.7% (CI 37.8–51.6%, SE 0.035, I2 = 0%, p = 0.662) for PD. The calculated difference was significant for EA compared to PD (p = 0.049) but not to SA (p = 0.524). Sensitivity analysis failed to reduce heterogeneity in the EA or SA group. We did not evaluate mortality or length of hospital stay as these data were only rarely reported. Sensitivity analysis failed to identify outliers that significantly influenced heterogeneity.
In addition, we evaluated the endoscopic publications for biliary/pancreatic duct stent implantation, submucosal injection and additional therapy that could influence the development of post-interventional complications. Thereby, papers also showed a high heterogeneity in this regard (Table 4). Sensitivity analysis failed to reduce heterogeneity of the calculated proportions as no single or systematic outliers could be identified.

3.4. Recurrence

In order to assess recurrence, we included data from 40 EA publications, 12 SA-datasets and 3 PD-datasets. The mean follow-up time was 44.7 months (EA), 49.6 months (SA) and 37.9 months (PD, all Table 3). The pooled means for recurrences were 13.0% (CI 10.2–15.6%) in EA, 9.4% (CI 4.8–14%) in SA and 14.2% (CI 9.5–18.9%) in PD. Heterogeneity was high in EA (I2 = 91.3%, p < 0.001) and SA (I2 = 57.3%, p = 0.007) but low in PD (I2 = 0%, p = 0.330). Proportion-meta-analysis showed pooled estimates of recurrence of 13.2% (CI 9.1–17.9%, SE 0.031, I2 = 88.4%, p < 0.001) in EA, 11.0% (CI 6.0–17.0%, SE 0.041, I2 = 48.9%, p = 0.028) in SA and 14.4% (9.8–19.7%, SE 0.035, I2 = 0%, p = 0.277) in PD (see Figure 4). Calculations revealed no statistical significance for recurrence for EA compared to SA (p = 0.536) or PD (p = 0.904).

3.5. Publication Bias

The calculation of funnel plots for reported R0-rates for EA (Figure 5A) and SA (Figure 5B) showed no evidence of publication bias. The p-values of the Egger’s test were 0.061 for EA and 0.229 for SA. We did not analyze publication bias for PD as less than 10 PD studies were included. Our data revealed no evidence for publication bias in regard to rates of complete resection.

4. Discussion

ALs are a rare but increasingly diagnosed entity. Although mainly benign and premalignant lesions are diagnosed, ALs have the potential for malignant transformation. In addition, ALs can cause cholangitis or pancreatitis and thereby reduce patients’ quality of life. Thus, treatment of ALs either by EA, SA or PD is indicated in all cases [2,3,4,80]. Nevertheless, prospective randomized trials comparing EA, SA or PD are lacking and the treatment of AL for non-invasive lesions, carcinoma in situ and T1-node-negative adenocarcinoma is far from a consensus. The choice of treatment is currently based on the decision of the treating clinician, and available endoscopic or surgical resources and is not supported by evidence-based guidelines.
This study is the first systematic review to report R0 resection rate, complications and recurrence of all three interventional procedures for the treatment of ALs. Our analyses clearly indicated a superiority of surgical approaches to endoscopic therapy with regard to complete resection (EA 76.6%, SA 96.4%, PD 98.9%). Nevertheless, this high efficacy was accompanied by a considerable rate of complications, in particular for PD (EA: 24.7%, SA: 28.3%, PD: 44.7%), but is possibly under-evaluated in these retrospective single cohort series. Statistical calculations indicate a significant difference between endoscopic and surgical interventions. One could argue that there is sufficient evidence to recommend surgery for invasive ALs as first line therapy. However, for non-invasive lesions or only suspicious one, especially in patients with high risk for surgical complications, the best approach remains to be determined. In addition, there is high heterogeneity and many limitations in the available literature.
First, we had to exclude numerous studies of PD data as they provided R0-rates and complications for the whole study populations including distal bile duct carcinoma, pancreatic cancer, duodenal lesions and all stages of ALs and ACs. As a consequence, distinct data of AAs or ACs (T1) could not be assessed. Therefore, many articles that presumably would fit our analysis had to be excluded. It is nevertheless unlikely that they would have significantly modified the R0 resection rate. Finally, only four publications of PD for ALs were eligible. Hence, we cannot exclude a publication bias as the Egger’s test required a minimum of 10 publications to sufficiently address this issue. Moreover, all PD papers analyzed data of ACs but not AAs or other ALs. Unfortunately, this finding leads to the assumption of a selection bias, as ACs are preferentially treated surgically rather than endoscopically. In addition, the selection of ACs could explain the low heterogeneity of PD data due to high similarity of included patients. In contrast, ACs were found only in 8.7% of EA patients and in 30.8% of SA data, which might reflect accurate patient selection. Indeed, in T1 adenocarcinoma, only those with an intact submucosal layer (D0) are eligible for local treatment (either EA or SA) as their likelihood of negativity in lymph node invasion is very high [81,82,83]. This may also have introduced a selection bias in the published data as described above. Finally, EUS should be used to evaluate ALs prior to intervention [84] but was mentioned in only 70.6% of surgical and 65.2% of EA studies. The inequality in ACs between the three interventional groups could also explain the similar rate of recurrence, although SA and PD showed a convincing rate of complete resection. A recurrence of a completely resected AA is more unlikely compared to a T1 AC, according to its nodal status. Additionally, recurrences were not described as local or distant, which is of utmost importance. The mean follow-up after procedure was possibly too low to catch all local recurrences.
Moreover, the histologic type (intestinal vs. pancreaticobiliary) and grade of dysplasia (low grade vs. high grade vs. T1d1 invasive lesion vs. T1d2 advanced lesion) also have an impact on outcome. It is acceptable to perform a second papillectomy for an initially incomplete resected AA rather than send for surgery. In contrast, an incidentally diagnosed AC, either incompletely resected or associated with a significant risk of lymph node involvement, might require additional surgery. In addition, it is important to report the subtypes of ACs (intestinal vs. pancreaticobiliary), as they influence the risk of local or distant recurrences [85]. However, the discrimination of AC subtypes was reported in only two of all included EA studies [23,65] and in none of the surgical series. It is also important to note that EA is a recent technique that has improved over the years, and results from the 1990s or early 2000 might not be as good as today, regarding patient’s selection, the rate of R0 resection and post procedure outcomes. Another important parameter to discriminate AAs from ACs, in particular in large ALs, is the molecular markers. A KRAS-mutation was found more often in advanced AAs and in ACs [86,87]. It is nevertheless important to note that KRAS mutation is an early event in tumorigenesis and can be found in early AA. Molecular markers in ALs are not sufficient to incorporate into our analysis but are interesting for future projects.
Another limitation of our meta-analysis is based on the design of the included studies. Almost all data were published in monocentric retrospective cohort studies. Prospective comparative randomized trials are lacking. Thus, the quality of the included studies is heterogeneous, only 59.4% of papers were of good quality according to NOS. In particular, the quality of EA data remains, at least in part, limited. Technical specifications of EA procedures have developed over the time and thus, different techniques were published. Moreover, the definition of R0 by histology and/or complete endoscopic resection was not used consistently in all studies. Beside the use of EUS, a prior ERCP procedure could influence results. Many publications did not report about prior sphincterotomy and, maybe more importantly, the use of pancreatic and bile duct stents was inhomogeneous. The current ESGE guidelines clearly recommend the implantation of a pancreatic duct stent to prevent post-ERCP-pancreatitis [88,89] in EA. A lot of EA data were published prior to these guidelines and, thus, did not regularly use pancreatic duct stents. Moreover, in 40.4% of patients with EA, a prior submucosal injection was performed to lift the lesions. A submucosal injection is not recommended as such injection resulted in reduced rates of complete resection [10,31,41,80]. Furthermore, in some EA studies, additional therapy by radiofrequency ablation (RFA), argon plasma coagulation (APC), additional EA or surgery was performed. All these confounders may have substantially influenced the results, in particular for complete resection, and could explain the high heterogeneity in EA studies. However, we aimed to reduce heterogeneity by different sensitivity analyses. Unfortunately, that results remain similar (success rates did not differ >10% between different analyses).
In addition to a complete resection, we analyzed the overall rate of complications between endoscopic and surgical interventions. The rate of complications was clearly higher in PD compared to EA, but not compared to SA. Since complications are defined very specifically with respect to every interventional approach and are difficult to compare, we decided to solely compare rates of overall complications. Moreover, if overall complications were reported in the included studies, most of them were not graded according to modern classifications such as Clavien–Dindo and it was not possible to accurately classify and compare them between PDD, SA and EA according to their severity. Therefore, our analysis is limited, as we cannot judge the burden of the reported adverse events. We think that an evaluation of severity of complications ought to be examined if there is an extension of in-patient time. In addition, the postoperative mortality of PD was not assessable in the present meta-analysis but should not been underestimated, as recently shown by nationwide data analyses [90,91].
Despite all the above mentioned limitations, our meta-analysis has some strengths. The baseline characteristics of age and gender were comparable between the three groups. Interestingly, the mean size of the lesions was quite similar (EA 19.7 mm, SA 17.5 mm, PD 17.0 mm). This finding was surprising, because large lesions are often more likely to be treated by surgery. But our finding is in line with current data indicating that there is no correlation of size and malignancy, if malignancy was excluded by EUS [11,14,17,92]. Hence, a selection bias depending on the size of the lesions is very unlikely.
Our results are in line with a recently published (non-systematic) meta-analysis of five studies summarizing that surgery was more effective compared to EA in AAs, but was associated with higher rates of complications [93]. However, this analysis showed several limitations in design and statistical analysis. The current data raised several questions that need to be addressed by further studies. Even if surgery is more effective in treating AL in our meta-analysis, a risk-benefit analysis has to be performed for PD according to the high rates of AEs. Another concern is the role of SA, as it is restricted to expert centers and not widely available, and might call for centralization in the management of such rare lesions. A more fundamental issue is the long-term outcome of repeated EA for recurrent AA. There are no data comparing repetitive EA with surgery for AA or EA as bridge to surgery.
From the present meta-analysis, very few of the included studies were comparative. Additionally, because of the heterogeneity in the reported variables, a strict comparison between the endoscopic and surgical groups was not possible to perform. In addition, with regard to PD, the use of laparoscopic and robotic-assisted PD is emerging. Retrospective studies showed comparable efficacy with reduced hospital stay and blood loss compared to open PD [94,95]. Nevertheless, recent published evidence failed to show the superiority or even equivalence of the laparoscopic approach to the Whipple procedure [96]. Indeed, a randomised controlled trial was stopped prematurely because of an excess of mortality in the laparoscopic group compared with the open approach [97]. In our meta-analysis, no studies analyzing laparoscopic or robotic-assisted PD could be included but these techniques might be interesting in future treatment of patients with advanced ALs.
To address these unanswered questions, a prospective randomized controlled trial should be initiated. Nevertheless, due to the rarity of ALs and lack of clear stratification attributes, this trial will not be realizable. This call for an international multicenter retrospective study that analyzes EA, SA and PD for AL in detail to provide evidence for therapeutic algorithms and data for the implementation of guidelines in the treatment of different types of ALs, including recurrent or incomplete resected lesions and additional ablative therapies [98].
In conclusion, the present meta-analysis provides an overview about the different therapeutic options for non-invasive ALs, carcinoma in situ and T1-node-negative adenocarcinoma. Our data suggest an improved rate of complete resection in surgical interventions compared to EA. But this benefit was accompanied by a significantly higher rate of complications, in particular after PD. However, high heterogeneity and limited data quality affect the reliability of data and results should be interpreted with caution. Further research is needed to establish clear guideline recommendations for the treatment of ALs.

Supplementary Materials

The following are available online at https://www.mdpi.com/2077-0383/9/11/3622/s1. Supplemental Material and methods.

Author Contributions

E.A.A., M.H., S.R. and S.G. designed the study; C.H., E.A.A., M.H., F.A. and A.G. performed the research, identified and scored the literature; M.H. wrote the manuscript; D.H. helped in statistical analysis. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

We acknowledge support from the German Research Foundation (DFG) and Universität Leipzig within the program of Open Access Publishing (to MH). This study was conducted as a project of the 9th Pancreas2000 education and research program funded by the Karolinska Institute, the European Pancreatic Club/EPC and the Acibadem Mehmet Ali Aydinlar University. CH, MH, AG, EAA and FA are mentees, SR and SG are mentors of this program. Pancreas2000 is a non-commercial post-graduation educational program of the European Pancreas Club (www.pancreas2000.org). For all participants catering and housing were covered by Pancreas2000 through an unrestricted educational grant. Pancreas2000 is a not-for-profit organization registered in Vienna, Austria (ZVR No. 1086784266). We would like to thank the Pancreas2000 program and specially Dawn M. Swibold, Malin Sund and Matthias Löhr for their constant and long-term support. We like to thank Patrick Maisonneuve for his constructive help in the analysis of the project’s data.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Abbreviations

AAampullary adenoma
ACampullary adenocarcinoma
AEadverse event
ALampullary lesion
APCArgon plasma coagulation
CIconfidence interval
EAEndoscopic ampullectomy
ESAPEndoscopic versus Surgical Ampullectomy vs Pancreaticoduodenectomy
FAPFamilial adenomatous polyposis
GISTGastrointestinal stroma tumor
MeSHmedical subject headings
NOSNewcastle-Ottawa-Scale
PDPancreaticoduodenectomy
PICO(S)Population Intervention Comparison Outcome Study
PRISMAPreferred Reporting Items for Systematic reviews and Meta-Analyses
RFARadiofrequency ablation
SASurgical ampullectomy

References

  1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71–96. [Google Scholar] [CrossRef] [PubMed]
  2. Albores-Saavedra, J.; Schwartz, A.M.; Batich, K.; Henson, D.E. Cancers of the ampulla of vater: Demographics, morphology, and survival based on 5,625 cases from the SEER program. J. Surg. Oncol. 2009, 100, 598–605. [Google Scholar] [CrossRef] [PubMed]
  3. Espinel, J.; Pinedo, E.; Ojeda, V.; Del Rio, M.G. Endoscopic management of adenomatous ampullary lesions. World J. Methodol. 2015, 5, 127–135. [Google Scholar] [CrossRef] [PubMed]
  4. Espinel, J.; Pinedo, E.; Ojeda, V.; Del Rio, M.G. Endoscopic ampullectomy: A technical review. Rev. Esp. Enferm. Dig. 2016, 108, 271–278. [Google Scholar] [CrossRef] [Green Version]
  5. Gibbs, E.R.; Walton, G.F.; Kent, R.B., 3rd; Laws, H.L. Villous tumors of the ampulla Vater. Am. Surg. 1997, 63, 467–471. [Google Scholar]
  6. El Hajj, I.I.; Coté, G.A. Endoscopic diagnosis and management of ampullary lesions. Gastrointest. Endosc. Clin. N. Am. 2013, 23, 95–109. [Google Scholar] [CrossRef]
  7. Binmoeller, K.F.; Boaventura, S.; Ramsperger, K.; Soehendra, N. Endoscopic snare excision of benign adenomas of the papilla of Vater. Gastrointest. Endosc. 1993, 39, 127–131. [Google Scholar] [CrossRef]
  8. Kahn, M.B.; Rush, B.F. The overlooked technique of ampullary excision. Surg. Gynecol. Obstet. 1989, 169, 253–254. [Google Scholar]
  9. Talamini, M.A.; Moesinger, R.C.; Pitt, H.A.; Sohn, T.A.; Hruban, R.H.; Lillemoe, K.D.; Yeo, C.J.; Cameron, J.L. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann. Surg. 1997, 225, 590–599. [Google Scholar] [CrossRef]
  10. De Palma, G.D. Endoscopic papillectomy: Indications, techniques, and results. World J. Gastroenterol. 2014, 20, 1537–1543. [Google Scholar] [CrossRef] [Green Version]
  11. Ito, K.; Fujita, N.; Noda, Y.; Kobayashi, G.; Obana, T.; Horaguchi, J.; Koshita, S.; Kanno, Y.; Ogawa, T.; Kato, Y.; et al. Impact of technical modification of endoscopic papillectomy for ampullary neoplasm on the occurrence of complications. Dig. Endosc. 2012, 24, 30–35. [Google Scholar] [CrossRef] [PubMed]
  12. Bohnacker, S.; Seitz, U.; Nguyen, D.; Thonke, F.; Seewald, S.; deWeerth, A.; Ponnadurai, R.; Omar, S.; Soehendra, N. Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. Gastrointest. Endosc. 2005, 62, 551–560. [Google Scholar] [CrossRef] [PubMed]
  13. Perez-Cuadrado-Robles, E.; Piessevaux, H.; Moreels, T.G.; Yeung, R.; Aouattah, T.; Komuta, M.; Dano, H.; Jouret-Mourin, A.; Deprez, P.H. Combined excision and ablation of ampullary tumors with biliary or pancreatic intraductal extension is effective even in malignant neoplasms. United Eur. Gastroenterol. J. 2019, 7, 369–376. [Google Scholar] [CrossRef] [Green Version]
  14. Ogawa, T.; Ito, K.; Fujita, N.; Noda, Y.; Kobayashi, G.; Horaguchi, J.; Koshita, S.; Kanno, Y.; Masu, K.; Ishii, S. Endoscopic papillectomy as a method of total biopsy for possible early ampullary cancer. Dig. Endosc. 2012, 24, 291. [Google Scholar] [CrossRef] [PubMed]
  15. Yamaguchi, K.; Enjoji, M.; Kitamura, K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest. Endosc. 1990, 36, 588–592. [Google Scholar] [CrossRef]
  16. Spadaccinie, M.; Fugazza, A.; Frazzoni, L.; Di Leo, M.; Auriemma, F.; Carrara, S.; Maselli, R.; Galtieri, P.A.; Chandrasekar, V.T.; Fuccio, L.; et al. Endoscopic papillectomy for neoplastic ampullary lesions: A systematic review with pooled analysis. United Eur. Gastroenterol. J. 2019, 8, 44–51. [Google Scholar] [CrossRef] [Green Version]
  17. Ito, K.; Noda, Y.; Fujita, N.; Horaguchi, J.; Kurose, A.; Sawai, T. Ampullary cancer with pancreas divisum treated by endoscopic partial papillectomy: A case report. J. Gastrointest. Liver Dis. 2011, 20, 205–207. [Google Scholar]
  18. Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015, 350, g7647. [Google Scholar] [CrossRef] [Green Version]
  19. Lo, C.K.; Mertz, D.; Loeb, M. Newcastle-Ottawa Scale: Comparing reviewers’ to authors’ assessments. BMC Med. Res. Methodol. 2014, 14, 45. [Google Scholar] [CrossRef] [Green Version]
  20. Sterne, J.A.; Gavaghan, D.; Egger, M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 2000, 53, 1119–1129. [Google Scholar] [CrossRef]
  21. Mccarty, T.R.; Rustagi, T. Comparative effectiveness and safety of radiofrequency ablation versus argon plasma coagulation for treatment of gastric antral vascular ectasia: A systematic review and meta-analysis. J. Clin. Gastroenterol. 2019, 53, 599–606. [Google Scholar] [CrossRef] [PubMed]
  22. Ahn, K.S.; Han, H.S.; Yoon, Y.S.; Cho, J.Y.; Khalikov, K. Laparoscopic transduodenal ampullectomy for benign ampullary tumors. J. Laparoendosc. Adv. Surg. Tech. 2010, 20, 59–63. [Google Scholar] [CrossRef] [PubMed]
  23. Alvarez-Sanchez, M.V.; Oria, I.; Luna, O.B.; Pialat, J.; Gincul, R.; Lefort, C.; Bourdariat, R.; Fumex, F.; Lepilliez, V.; Scoazec, J.Y.; et al. Can endoscopic papillectomy be curative for early ampullary adenocarcinoma of the ampulla of Vater? Surg. Endosc. 2017, 31, 1564–1572. [Google Scholar] [CrossRef] [PubMed]
  24. Amini, A.; Miura, J.T.; Jayakrishnan, T.T.; Johnston, F.M.; Tsai, S.; Christians, K.K.; Gamblin, T.C.; Turaga, K.K. Is local resection adequate for T1 stage ampullary cancer? HPB 2015, 17, 66–71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Bellizzi, A.M.; Kahaleh, M.; Stelow, E.B. The assessment of specimens procured by endoscopic ampullectomy. Am. J. Clin. Pathol. 2009, 132, 506–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Boix, J.; Lorenzo-Zuniga, V.; de Vega, V.M.; Domènech, E.; Gassull, M.A. Endoscopic resection of ampullary tumors: 12-year review of 21 cases. Surg. Endosc. 2009, 23, 45–49. [Google Scholar] [CrossRef]
  27. Catalano, M.F.; Linder, J.D.; Chak, A.; Sivak, M.V., Jr.; Raijman, I.; Geenen, J.E.; Howell, D.A. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest. Endosc. 2004, 59, 225–232. [Google Scholar] [CrossRef]
  28. Ceppa, E.P.; Burbridge, R.A.; Rialon, K.L.; Omotosho, P.A.; Emick, D.; Jowell, P.S.; Branch, M.S.; Pappas, T.N. Endoscopic versus surgical ampullectomy: An algorithm to treat disease of the ampulla of Vater. Ann. Surg. 2013, 257, 315–322. [Google Scholar] [CrossRef]
  29. Chang, W.I.; Min, Y.W.; Yun, H.S.; Lee, K.H.; Lee, J.K.; Lee, K.T.; Rhee, P.L. Prophylactic pancreatic stent placement for endoscopic duodenal ampullectomy: A single-center retrospective study. Gut Liver 2014, 8, 306–312. [Google Scholar] [CrossRef] [Green Version]
  30. Cheng, C.L.; Sherman, S.; Fogel, E.L.; McHenry, L.; Watkins, J.L.; Fukushima, T.; Howard, T.J.; Lazzell-Pannell, L.; Lehman, G.A. Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest. Endosc. 2004, 60, 757–764. [Google Scholar] [CrossRef]
  31. Chung, K.H.; Lee, S.H.; Choi, J.H.; Kang, J.; Paik, W.H.; Ahn, D.W.; Ryu, J.K.; Kim, Y.T. Effect of submucosal injection in endoscopic papillectomy of ampullary tumor: Propensity-score matching analysis. United Eur. Gastroenterol. J. 2018, 6, 576–585. [Google Scholar] [CrossRef] [PubMed]
  32. De Palma, G.D.; Luglio, G.; Maione, F.; Esposito, D.; Siciliano, S.; Gennarelli, N.; Cassese, G.; Persico, M.; Forestieri, P. Endoscopic snare papillectomy: A single institutional experience of a standardized technique. A retrospective cohort study. Int. J. Surg. 2015, 13, 180–183. [Google Scholar] [CrossRef] [PubMed]
  33. Demetriades, H.; Zacharakis, E.; Kirou, I.; Pramateftakis, M.G.; Sapidis, N.; Kanellos, I.; Betsis, D. Local excision as a treatment for tumors of ampulla of Vater. World J. Surg. Oncol. 2006, 4, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Desilets, D.J.; Dy, R.M.; Ku, P.M.; Hanson, B.L.; Mattia, A.; Howell, D.A. Endoscopic management of tumors of the major duodenal papilla: Refined techniques to improve outcome and avoid complications. Gastrointest. Endosc. 2001, 54, 202–208. [Google Scholar] [CrossRef]
  35. Dixon, E.; Vollmer, C.M., Jr.; Sahajpal, A.; Cattral, M.S.; Grant, D.R.; Taylor, B.R.; Langer, B.; Gallinger, S.; Greig, P.D. Transduodenal resection of peri-ampullary lesions. World J. Surg. 2005, 29, 649–652. [Google Scholar] [CrossRef] [PubMed]
  36. Dubois, M.; Labgaa, I.; Dorta, G.; Halkic, N. Endoscopic and surgical ampullectomy for non-invasive ampullary tumors: Short-term outcomes. Biosci. Trends 2017, 10, 507–511. [Google Scholar] [CrossRef] [Green Version]
  37. Gao, Y.; Zhu, Y.; Huang, X.; Wang, H.; Huang, X.; Yuan, Z. Transduodenal ampullectomy provides a less invasive technique to cure early ampullary cancer. BMC Surg. 2016, 16, 36. [Google Scholar] [CrossRef] [Green Version]
  38. Grobmyer, S.R.; Stasik, C.N.; Dragonov, P.; Hemming, A.W.; Dixon, L.R.; Vogel, S.B.; Hochwald, S.N. Contemporary results with ampullectomy for 29 “benign” neoplasms of the ampulla. J. Am. Coll. Surg. 2008, 206, 466–471. [Google Scholar] [CrossRef]
  39. Harano, M.; Ryozawa, S.; Iwano, H.; Taba, K.; Sen-Yo, M.; Sakaida, I. Clinical impact of endoscopic papillectomy for benign-malignant borderline lesions of the major duodenal papilla. J. Hepato Biliary Pancreat. Sci. 2011, 18, 190–194. [Google Scholar] [CrossRef]
  40. Hong, S.; Song, K.B.; Lee, Y.J.; Park, K.M.; Kim, S.C.; Hwang, D.W.; Lee, J.H.; Shin, S.H.; Kwon, J.; Ma, C.H.; et al. Transduodenal ampullectomy for ampullary tumors—Single center experience of consecutive 26 patients. Ann. Surg. Treat. Res. 2018, 95, 22–28. [Google Scholar] [CrossRef]
  41. Hyun, J.J.; Lee, T.H.; Park, J.S.; Han, J.H.; Jeong, S.; Park, S.M.; Lee, H.S.; Moon, J.H.; Park, S.H. A prospective multicenter study of submucosal injection to improve endoscopic snare papillectomy for ampullary adenoma. Gastrointest. Endosc. 2017, 85, 746–755. [Google Scholar] [CrossRef] [PubMed]
  42. Igarashi, Y.; Okano, N.; Ito, K.; Mimura, T.; Nakano, S. Endoscopic snare excision of a major duodenal papillary tumor. Dig. Surg. 2010, 27, 119–122. [Google Scholar] [CrossRef] [PubMed]
  43. Irani, S.; Arai, A.; Ayub, K.; Biehl, T.; Brandabur, J.J.; Dorer, R.; Gluck, M.; Jiranek, G.; Patterson, D.; Schembre, D.; et al. Papillectomy for ampullary neoplasm: Results of a single referral center over a 10-year period. Gastrointest. Endosc. 2009, 70, 923–932. [Google Scholar] [CrossRef] [PubMed]
  44. Ismail, S.; Marianne, U.; Heikki, J.; Jorma, H.; Leena, K. Endoscopic papillectomy, single-centre experience. Surg. Endosc. 2014, 28, 3234–3239. [Google Scholar] [CrossRef]
  45. Jeanniard-Malet, O.; Caillol, F.; Pesenti, C.; Bories, E.; Monges, G.; Giovannini, M. Short-term results of 42 endoscopic ampullectomies: A single-center experience. Scand. J. Gastroenterol. 2011, 46, 1014–1019. [Google Scholar] [CrossRef]
  46. Jung, S.; Kim, M.H.; Seo, D.W.; Lee, S.K. Endoscopic snare papillectomy of adenocarcinoma of the major duodenal papilla. Gastrointest. Endosc. 2001, 54, 622. [Google Scholar] [CrossRef]
  47. Kahaleh, M.; Shami, V.M.; Brock, A.; Conaway, M.R.; Yoshida, C.; Moskaluk, C.A.; Adams, R.B.; Tokar, J.; Yeaton, P. Factors predictive of malignancy and endoscopic resectability in ampullary neoplasia. Am. J. Gastroenterol. 2004, 99, 2335–2339. [Google Scholar] [CrossRef]
  48. Kang, S.H.; Kim, K.H.; Kim, T.N.; Jung, M.K.; Cho, C.M.; Cho, K.B.; Han, J.M.; Kim, H.G.; Kim, H.S. Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: Retrospective analysis of a multicenter study. BMC Gastroenterol. 2017, 17, 69. [Google Scholar] [CrossRef]
  49. Katsinelos, P.; Kountouras, J.; Chatzimavroudis, G.; Zavos, C.; Paroutoglou, G.; Kotakidou, R.; Panagiotopoulou, K.; Papaziogas, B. A case of early depressed-type ampullary carcinoma treated by wire-guided endoscopic resection. Surg. Laparosc. Endosc. Percutaneous Tech. 2007, 17, 533–537. [Google Scholar] [CrossRef]
  50. Kim, S.H.; Moon, J.H.; Choi, H.J.; Kim, D.C.; Lee, T.H.; Cheon, Y.K.; Cho, Y.D.; Park, S.H.; Kim, S.J. Usefulness of pancreatic duct wire-guided endoscopic papillectomy for ampullary adenoma for preventing post-procedure pancreatitis. Endoscopy 2013, 45, 838–841. [Google Scholar] [CrossRef]
  51. Kim, A.L.; Choi, Y.I. Safety of duodenal ampullectomy for benign periampullary tumors. Ann. Hepato Biliary Pancreat. Surg. 2017, 21, 146–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Kim, J.; Choi, S.H.; Choi, D.W.; Heo, J.S.; Jang, K.T. Role of transduodenal ampullectomy for tumors of the ampulla of Vater. J. Korean Surg. Soc. 2011, 81, 250–256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Klein, A.; Qi, Z.; Bahin, F.F.; Awadie, H.; Nayyar, D.; Ma, M.; Voermans, R.P.; Williams, S.J.; Lee, E.; Bourke, M.J. Outcomes after endoscopic resection of large laterally spreading lesions of the papilla and conventional ampullary adenomas are equivalent. Endoscopy 2018, 50, 972–983. [Google Scholar]
  54. Lee, H.; Park, J.Y.; Kwon, W.; Heo, J.S.; Choi, D.W.; Choi, S.H. Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. World J. Surg. 2016, 40, 967–973. [Google Scholar] [CrossRef] [PubMed]
  55. Lee, T.Y.; Cheon, Y.K.; Shim, C.S.; Choi, H.J.; Moon, J.H.; Choi, J.S.; Oh, H.C. Endoscopic wire-guided papillectomy versus conventional papillectomy for ampullary tumors: A prospective comparative pilot study. J. Gastroenterol. Hepatol. 2016, 31, 897–902. [Google Scholar] [CrossRef] [PubMed]
  56. Ma, T.; Jang, E.J.; Zukerberg, L.R.; Odze, R.; Gala, M.K.; Kelsey, P.B.; Forcione, D.G.; Brugge, W.R.; Casey, B.W.; Syngal, S.; et al. Recurrences are common after endoscopic ampullectomy for adenoma in the familial adenomatous polyposis (FAP) syndrome. Surg. Endosc. 2014, 28, 2349–2356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Maguchi, H.; Takahashi, K.; Katanuma, A.; Hayashi, T.; Yoshida, A. Indication of endoscopic papillectomy for tumors of the papilla of vater and its problems. Dig. Endosc. 2003, 15, S33–S35. [Google Scholar] [CrossRef]
  58. Mansukhani, V.M.; Desai, G.S.; Mouli, S.; Shirodkar, K.; Shah, R.C.; Palepu, J. Transduodenal ampullectomy for ampullary tumors. Indian J. Gastroenterol. 2017, 36, 62–65. [Google Scholar] [CrossRef]
  59. Napoleon, B.; Gincul, R.; Ponchon, T.; Berhiller, J.; Escourrou, J.; Canard, J.M.; Boyer, J.; Barthet, M.; Ponsot, P.; Laugier, R.; et al. Endoscopic papillectomy for early ampullary tumors: Long-term results from a large multicenter prospective study. Endoscopy 2014, 46, 127–134. [Google Scholar] [CrossRef]
  60. Nguyen, N.; Shah, J.N.; Binmoeller, K.F. Outcomes of endoscopic papillectomy in elderly patients with ampullary adenoma or early carcinoma. Endoscopy 2010, 42, 975–977. [Google Scholar] [CrossRef]
  61. Norton, I.D.; Gostout, C.J.; Baron, T.H.; Geller, A.; Petersen, B.T.; Wiersema, M.J. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest. Endosc. 2002, 56, 239–243. [Google Scholar] [CrossRef]
  62. Onkendi, E.O.; Naik, N.D.; Rosedahl, J.K.; Harmsen, S.W.; Gostout, C.J.; Baron, T.H., Sr.; Sarr, M.G.; Que, F.G. Adenomas of the ampulla of Vater: A comparison of outcomes of operative and endoscopic resections. J. Gastrointest. Surg. 2014, 18, 1588–1596. [Google Scholar] [CrossRef]
  63. Ouaissi, M.; Sielezneff, I.; Alves, A.; Pirro, N.; Heyries, L.; Robitail, S.; Consentino, B.; Payan, M.J.; Valleur, P.; Panis, Y.; et al. Long term outcome following 26 surgical ampullectomies. Ann. Chir. 2006, 131, 322–327. [Google Scholar] [PubMed]
  64. Patel, R.; Davitte, J.; Varadarajulu, S.; Wilcox, C.M. Endoscopic resection of ampullary adenomas: Complications and outcomes. Dig. Dis. Sci. 2011, 56, 3235–3240. [Google Scholar] [CrossRef] [PubMed]
  65. Petrone, G.; Ricci, R.; Familiari, P.; Inzani, F.; Matsuoka, M.; Mutignani, M.; Delle Fave, G.; Costamagna, G.; Rindi, G. Endoscopic snare papillectomy: A possible radical treatment for a subgroup of T1 ampullary adenocarcinomas. Endoscopy 2013, 45, 401–404. [Google Scholar] [CrossRef]
  66. Poincloux, L.; Scanzi, J.; Goutte, M.; Pereira, B.; Devaud, H.; Joubert, J.; Dapoigny, M.; Bommelaer, G.; Abergel, A. Pancreatic intubation facilitated by methylene blue injection decreases the risk for postpapillectomy acute pancreatitis. Eur. J. Gastroenterol. Hepatol. 2014, 26, 990–995. [Google Scholar] [CrossRef]
  67. Ridtitid, W.; Schmidt, S.E.; Al-Haddad, M.A.; LeBlanc, J.; DeWitt, J.M.; McHenry, L.; Fogel, E.L.; Watkins, J.L.; Lehman, G.A.; Sherman, S.; et al. Performance characteristics of EUS for locoregional evaluation of ampullary lesions. Gastrointest. Endosc. 2015, 81, 380–388. [Google Scholar] [CrossRef] [Green Version]
  68. Salmi, S.; Ezzedine, S.; Vitton, V.; Ménard, C.; Gonzales, J.M.; Desjeux, A.; Grimaud, J.C.; Barthet, M. Can papillary carcinomas be treated by endoscopic ampullectomy? Surg. Endosc. 2012, 26, 920–925. [Google Scholar] [CrossRef]
  69. Schneider, L.; Contin, P.; Fritz, S.; Strobel, O.; Büchler, M.W.; Hackert, T. Surgical ampullectomy: An underestimated operation in the era of endoscopy. HPB 2016, 18, 65–71. [Google Scholar] [CrossRef] [Green Version]
  70. Shim, C.N.; Chung, M.J.; Bang, S.; Park, S.W.; Song, S.Y.; Chung, J.B.; Park, J.Y. Clinicopathologic characteristics associated with complications and long-term outcomes of endoscopic papillectomy for adenoma. Yonsei Med. J. 2014, 55, 644–650. [Google Scholar] [CrossRef] [Green Version]
  71. Stiles, Z.E.; Behrman, S.W.; Deneve, J.L.; Glazer, E.S.; Dong, L.; Wan, J.Y.; Martin, M.G.; Dickson, P.V. Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease. J. Surg. Oncol. 2018, 117, 1500–1508. [Google Scholar] [CrossRef]
  72. Treitschke, F.; Beger, H.G. Local resection of benign periampullary tumors. Ann. Oncol. 1999, 10 (Suppl. 4), 212–214. [Google Scholar] [CrossRef] [PubMed]
  73. Tsuji, S.; Itoi, T.; Sofuni, A.; Mukai, S.; Tonozuka, R.; Moriyasu, F. Tips and tricks in endoscopic papillectomy of ampullary tumors: Single-center experience with large case series (with videos). J. Hepato Biliary Pancreat. Sci. 2015, 22, E22–E27. [Google Scholar] [CrossRef] [PubMed]
  74. Van der Wiel, S.E.; Poley, J.W.; Koch, A.D.; Bruno, M.J. Endoscopic resection of advanced ampullary adenomas: A single-center 14-year retrospective cohort study. Surg. Endosc. 2019, 33, 1180–1188. [Google Scholar] [CrossRef] [Green Version]
  75. Will, U.; Muller, A.K.; Fueldner, F.; Wanzar, I.; Meyer, F. Endoscopic papillectomy: Data of a prospective observational study. World J. Gastroenterol. 2013, 19, 4316–4324. [Google Scholar] [CrossRef] [PubMed]
  76. Yamamoto, K.; Itoi, T.; Sofuni, A.; Tsuchiya, T.; Tanaka, R.; Tonuzuka, R.; Honjo, M.; Mukai, S.; Fujita, M.; Asai, Y.; et al. Expanding the indication of endoscopic papillectomy for T1a ampullary carcinoma. Dig. Endosc. 2019, 31, 188–196. [Google Scholar] [CrossRef]
  77. Yamao, T.; Isomoto, H.; Kohno, S.; Mizuta, Y.; Yamakawa, M.; Nakao, K.; Irie, J. Endoscopic snare papillectomy with biliary and pancreatic stent placement for tumors of the major duodenal papilla. Surg. Endosc. 2010, 24, 119–124. [Google Scholar] [CrossRef]
  78. Yoon, S.M.; Kim, M.H.; Kim, M.J.; Jang, S.J.; Lee, T.Y.; Kwon, S.; Oh, S.C.; Lee, S.S.; Seo, D.W.; Lee, S.K. Focal early stage cancer in ampullary adenoma: Surgery or endoscopic papillectomy? Gastrointest. Endosc. 2007, 66, 701–707. [Google Scholar] [CrossRef] [Green Version]
  79. Zadorova, Z.; Dvofak, M.; Hajer, J. Endoscopic therapy of benign tumors of the papilla of Vater. Endoscopy 2001, 33, 345–347. [Google Scholar] [CrossRef]
  80. Ardengh, J.C.; Kemp, R.; Lima-Filho, E.R.; Dos Santos, J.S. Endoscopic papillectomy: The limits of the indication, technique and results. World J. Gastrointest. Endosc. 2015, 7, 987–994. [Google Scholar] [CrossRef]
  81. Beger, H.G.; Treitschke, F.; Gansauge, F.; Harada, N.; Hiki, N.; Mattfeldt, T. Tumor of the ampulla of Vater: Experience with local or radical resection in 171 consecutively treated patients. Arch. Surg. 1999, 134, 526–532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Winter, J.M.; Cameron, J.L.; Olino, K.; Herman, J.M.; de Jong, M.C.; Hruban, R.H.; Wolfgang, C.L.; Eckhauser, F.; Edil, B.H.; Choti, M.A.; et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: Implications for surgical strategy and long-term prognosis. J. Gastrointest. Surg. 2010, 14, 379–387. [Google Scholar] [CrossRef] [PubMed]
  83. Yoon, Y.S.; Kim, S.W.; Park, S.J.; Lee, H.S.; Jang, J.Y.; Choi, M.G.; Kim, W.H.; Lee, K.U.; Park, Y.H. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann. Surg. 2005, 242, 92–100. [Google Scholar] [CrossRef] [PubMed]
  84. Bassan, M.; Bourke, M. Endoscopic ampullectomy: A practical guide. J. Interv. Gastroenterol. 2012, 2, 23–30. [Google Scholar] [CrossRef] [Green Version]
  85. Chang, D.K.; Jamieson, N.B.; Johns, A.L.; Scarlett, C.J.; Pajic, M.; Chou, A.; Pinese, M.; Humphris, J.L.; Jones, M.D.; Toon, C.; et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J. Clin. Oncol. 2013, 10, 1348–1356. [Google Scholar] [CrossRef]
  86. Agoritsas, T.; Merglen, A.; Courvoisier, D.S.; Combescure, C.; Garin, N.; Perrier, A.; Perneger, T.V. Sensitivity and predictive value of 15 PubMed search strategies to answer clinical questions rated against full systematic reviews. J. Med. Internet Res. 2012, 14, e85. [Google Scholar] [CrossRef]
  87. Haraldsson, E.; Swahn, F.; Verbeke, C.; Mattsson, J.S.M.; Enochsson, L.; Ung, K.A.; Lundell, L.; Heuchel, R.; Löhr, J.M.; Arnelo, U. Endoscopic papillectomy and KRAS expression in the treatment of adenoma in the major duodenal papilla. Scand. J. Gastroenterol. 2015, 50, 1419–1427. [Google Scholar] [CrossRef] [Green Version]
  88. Dumonceau, J.M.; Andriulli, A.; Elmunzer, B.J.; Mariani, A.; Meister, T.; Deviere, J.; Marek, T.; Baron, T.H.; Hassan, C.; Testoni, P.A.; et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline—Updated June 2014. Endoscopy 2014, 46, 799–815. [Google Scholar] [CrossRef] [Green Version]
  89. Testoni, P.A.; Mariani, A.; Aabakken, L.; Arvanitakis, M.; Bories, E.; Costamagna, G.; Devière, J.; Dinis-Ribeiro, M.; Dumonceau, J.M.; Giovannini, M.; et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2016, 48, 657–683. [Google Scholar] [CrossRef]
  90. Farges, O.; Bendersky, N.; Truant, S.; Delpero, J.R.; Pruvot, F.R.; Sauvanet, A. The theory and practice of pancreatic surgery in France. Ann. Surg. 2017, 266, 797–804. [Google Scholar] [CrossRef]
  91. Nimptsch, U.; Krautz, C.; Weber, G.F.; Mansky, T.; Grützmann, R. Nationwide in-hospital mortality following pancreatic surgery in Germany is higher than anticipated. Ann. Surg. 2016, 264, 1082–1090. [Google Scholar] [CrossRef] [PubMed]
  92. Ito, K.; Fujita, N.; Noda, Y.; Kobayashi, G.; Horaguchi, J.; Takasawa, O.; Obana, T. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: A prospective and histopathologically controlled study. Gastrointest. Endosc. 2007, 66, 740–747. [Google Scholar] [CrossRef] [PubMed]
  93. Mendonca, E.Q.; Bernardo, W.M.; Moura, E.G.H.; Chaves, D.M.; Kondo, A.; Pu, L.Z.; Baracat, F.I. Endoscopic versus surgical treatment of ampullary adenomas: A systematic review and meta-analysis. Clinics 2016, 71, 28–35. [Google Scholar] [CrossRef]
  94. Liu, M.; Shunrong, J.; Xu, W.; Liu, W.; Qin, Y.; Hu, Q.; Sun, Q.; Zhang, Z.; Yu, X.; Xu, X. Laparoscopic pancreaticoduodenectomy: Are the best times coming? World J. Surg. Oncol. 2019, 10, 1624–1626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Marino, M.V.; Podda, M.; Ruiz, M.G.; Fernandez, C.G.; Guarrasi, D.; Fleitas, M.G. Robotic-assisted versus open pancreaticoduodenectomy: The results of a case-matched comparison. J. Robot. Surg. 2020, 14, 493–502. [Google Scholar] [CrossRef]
  96. Nickel, F.; Haney, C.M.; Kowalewski, K.F.; Probst, P.; Limen, E.F.; Kalkum, E.; Diener, M.K.; Strobel, O.; Müller-Stich, B.P.; Hackert, T. Laparoscopic versus open pancreaticoduodenectomy: A systematic review and meta-analysis of randomized controlled trials. Ann. Surg. 2020, 1, 54–66. [Google Scholar] [CrossRef]
  97. Van Hilst, J.; de Rooij, T.; Bosscha, K.; Brinkman, D.J.; van Dieren, S.; Dijkgraaf, M.G.; Gerhards, M.F.; de Hingh, I.H.; Karsten, T.M.; Lips, D.J.; et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): A multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol. Hepatol. 2019, 4, 199–207. [Google Scholar] [CrossRef]
  98. Hollenbach, M.; Auriemma, F. Endoscopic vs. surgical ampullectomy vs. pancreatitcoduodenectomy (ESAP) for ampullary neoplasm—A Pancreas2000/EPC study group. Pancreatology 2019, 19, S166. [Google Scholar] [CrossRef]
Jcm 09 03622 g001 550
Figure 1. Flow chart of the study selection process. Out of 2395 search results, 59 papers were finally included in the analysis. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Figure 1. Flow chart of the study selection process. Out of 2395 search results, 59 papers were finally included in the analysis. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Jcm 09 03622 g001
Jcm 09 03622 g002a 550Jcm 09 03622 g002b 550
Figure 2. Complete resection in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plots for EA (A), SA (B) and PD (C). Pooled R0 rates were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting was used for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Figure 2. Complete resection in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plots for EA (A), SA (B) and PD (C). Pooled R0 rates were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting was used for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Jcm 09 03622 g002aJcm 09 03622 g002b
Jcm 09 03622 g003 550
Figure 3. Complications in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plot for EA (A), SA (B) and PD (C). Pooled rates of complications were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy, AP: acute pancreatitis, NA: not available.
Figure 3. Complications in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plot for EA (A), SA (B) and PD (C). Pooled rates of complications were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy, AP: acute pancreatitis, NA: not available.
Jcm 09 03622 g003
Jcm 09 03622 g004a 550Jcm 09 03622 g004b 550
Figure 4. Recurrence in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plots for EA (A), SA (B) and PD (C). Pooled rates of recurrence were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting was used for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Figure 4. Recurrence in endoscopic and surgical intervention. Proportions of meta-analyses were calculated and shown as forrest-plots for EA (A), SA (B) and PD (C). Pooled rates of recurrence were calculated to obtain a proportion with a 95% confidence interval (CI). The binary random effects model (DerSimonian–Laird) was used for EA and SA and a fixed effect model with inverse variance weighting was used for PD. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Jcm 09 03622 g004aJcm 09 03622 g004b
Jcm 09 03622 g005 550
Figure 5. Analysis of publication bias. Funnel plots were drawn for EA (A) and SA (B) indicating no evidence of publication bias. Funnel plots were not used for PD as less than 10 PD papers were included in the meta-analysis. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Figure 5. Analysis of publication bias. Funnel plots were drawn for EA (A) and SA (B) indicating no evidence of publication bias. Funnel plots were not used for PD as less than 10 PD papers were included in the meta-analysis. EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Jcm 09 03622 g005
Table
Table 1. Evalulation of the included studies.
Table 1. Evalulation of the included studies.
Study 1st AuthorYearNOS-ScoreSelection I.1Selection I.2Selection I.3Selection I.4Comparability IIOutcome III.1Outcome III.2Outcome III.3
Ahn2013711101111
Alvarez-Sanchez2017711101111
Amini2014811111111
Bellizzi2009610110111
Boix2009510110110
Catalano2004711101111
Ceppa2013911112111
Chang2014610110111
Cheng2004610110111
Chung2018611101110
De Palma2015711101111
Demetriades2006710111111
Desilets2001711101111
Dixon2005610101111
Dubois2016911112111
Gao2016811111111
Grobmyer2008811111111
Harano2011711101111
Hong2018710111111
Hyun2017601101111
Igarashi2010610110111
Irani2009911112111
Ismail2014610110111
Jeanniard-Malet2011610110111
Jung2009510110110
Kahaleh2004411100100
Kang2017610110111
Katsinelos2006610110111
Kim a2013610110111
Kim c2017811111111
Kim b2011811111111
Klein2018911112111
Lee a2016711101111
Lee b2016811111111
Ma2014610110111
Maguchi2003611100111
Mansukhani2017710111111
Napoleon2014711101111
Nguyen2010711101111
Norton2002610110111
Onkendi2014811111111
Ouaïssi2006711110111
Patel2011610110111
Petrone2013711101111
Poincloux2014711101111
Ridtitid2014610110111
Salmi2012711101111
Schneider2016711111110
Shim2014711101111
Stiles2018811111111
Treitschke1999710111111
Tsuji2015610110111
Van der Wiel2018610110111
Will2013610110111
Yamamoto2018711101111
Yamao2010610110111
Yoon2005711111110
Yoon2007811111111
Zadorova2001611100111
Overview over all rated publications in our Systemativ Review, using the Newcastel-Ottawa-Score. Green shows good, yellow mediocre and red low reporting quality.
Table
Table 2. Characteristics of the included studies.
Table 2. Characteristics of the included studies.
Study 1st AuthorYearCountryPatientsPeriod StartEndDesignProcedure
Ahn2013Korearetrospective20062009monocentricEA
Alvarez-Sanchez2017Franceretrospective05/199909/2013monocentricEA
Amini2014USAretrospective20042010register, multicentricEA, SA, PD
Bellizzi2009USAretrospectiveNANAmonocentricEA
Boix2009Spainretrospective01/199502/2007monocentricEA
Catalano2004USAretrospective19982001mulitcentricEA
Ceppa2013USAretrospective19912010monocentricEA, SA
Chang2014Korearetrospective08/200206/2011monocentricEA
Cheng2004USAretrospective19942003monocentricEA
Chung2018Korearetrospective03/200603/2014monocentricEA
De Palma2015Italyretrospective20082013monocentricEA
Demetriades2006Greeceretrospective19902004monocentricSA
Desilets2001USAretrospective19912000monocentricEA
Dixon2005Canadaretrospective19922002mulitcentricSA
Dubois2016Switzerland retrospective20052015monocentricEA, SA
Gao2016Chinaretrospective01/200112/2014monocentricSA, PD
Grobmyer2008USAretrospective01/199112/2006monocentricSA
Harano2011Japanretrospective11/199507/2009monocentricEA
Hong2018Korearetrospective20042016monocentricSA
Hyun2017Koreaprospective, randomized01/201412/2015multicentricEA
Igarashi2010Japanretrospective10/200203/2009monocentricEA
Irani2009USAretrospective19972007monocentricEA
Ismail2014Finlandretrospective20002012monocentricEA
Jeanniard-Malet2011Franceretrospective12/200311/2008monocentricEA
Jung2009Korearetrospective07/200306/2008monocentricEA
Kahaleh2004USAretrospective03/200005/2003monocentricEA
Kang2017Korearetrospective01/200707/2014multicentricEA
Katsinelos2006Greeceretrospective19982004monocentricEA
Kim a2013Korearetrospective09/200503/2012monocentricEA
Kim b2011Korearetrospective01/199912/2008monocentricEA, SA
Kim c2017Korearetrospective01/200109/2016monocentricEA, SA
Klein2018Australiaretrospective201806/2017monocentricEA
Lee a2016Koreaprospective randomized01/201207/2014multicentricEA
Lee b2016Korearetrospective09/199406/2013monocentricSA, PD
Ma2014USAretrospective19992010multicentricEA
Maguchi2003Japanretrospective04/199710/2002monocentricEA
Mansukhani2017Indiaretrospective20092015monocentricSA
Napoleon2014Franceprospective09/200301/2006mulitcentricEA
Nguyen2010USAretrospectiveNANAmonocentricEA
Norton2002USAretrospective09/199711/1999monocentricEA
Onkendi2014USAretrospective19942009monocentricEA, SA, PD
Ouaïssi2006Franceretrospective19812004monocentricSA
Patel2011USAretrospective05/199608/2009monocentricEA
Petrone2013Italyretrospective10/200006/2009monocentricEA
Poincloux2014Franceretrospective20042011monocentricEA
Ridtitid2014USAretrospective07/199507/2012monocentricEA
Salmi2012Franceretrospective02/200212/2008monocentricEA
Schneider2016Germanyprospective20012014monocentricSA
Shim2014Korearetrospective09/200604/2012monocentricEA
Stiles2018USAretrospective20042014register, multicentreSA, PD
Treitschke1999Germanyretrospective19831999monocentricSA, PD
Tsuji2015Japanretrospective05/199904/2014monocentricEA
Van der Wiel2018The Netherlandsretrospective20022016monocentricEA
Will2013GermanyprospectiveNANAmulticentricEA
Yamamoto2018Japanretrospective05/199912/2016monocentricEA
Yamao2010Japanretrospective09/200006/2008monocentricEA
Yoon2005Korearetrospective19862002monocentricPD
Yoon2007Korearetrospective19962006monocentricEA, SA
Zadorova2001Czech Republicretrospective19941999monocentricEA
EA: endoscopic ampullectomy, SA: surgical ampullectomy, PD: pancreaticoduodenectomy.
Table
Table 3. Outcomes of the included studies.
Table 3. Outcomes of the included studies.
Study 1st AuthorYearTypeNumber% MaleAge (y)Lesion Size (mm)R0 (%)Recurrence %Follow-Up (m)Complications OverallAPBleedingPerforationInfectionStenosisLeakageOthers% Adenoma% Adeno-CaHereditary SyndromsAsymptomatic %
Ahn2013EA43NAN15741410.432.616.39.3NA4.72.3NANA10000100
Alvarez-Sanchez2017EA286171.318435828NANANANANANANANANANA0100
Bellizzi2009EA456062.9NA34.87312NANANANANANANANA9.100NA
Boix2009EA214367.2NA28.616.715.923.8194.80NA0NANA52.447.600
Catalano2004EA1034853.122.8NA9.7369.74.91.9NANA2.9NANA80.65.80NA
Ceppa2013EA684757,8NA80NANA1899NANANANANANANA0NA
Chang2014EA8265.954.71392.76.624.2NA9.812.2001.2NANA91.5NA045
Cheng2004EA554059NA73.733.33014.59.129.11.8NA3.6NANA100052.429.1
Chung2018EA12253.358.2NA49.212.382NA13.98.21,64.14.9NANA95.92.5052.5
De Palma2015EA2762.9682392.63.718.418.511.17.4NANANANANANANA025.9
Desilets2001EA41566824.791.30194.92,42.40000NA41.536.60NA
Dubois2016EA1163.66515NANANA9.1NANANANANANANANA013.9NA
Harano2011EA286166.617079066NA71807NANANA1739.30100
Hyun2017EA504860.7116610.912NA2044224NANA10000100
Igarashi2010EA36506616.3NA8.3NA55.6301702.85.6NANANANA0100
Irani2009EA102NANA2484.37.8NA20.69.84.9212.9NANANANA0NA
Ismail2014EA6162.2NANA52.3NANA24.69.8183.3NANANANA78.716.4019.7
Jeanniard-Malet2011EA4254.863NA92.912.11523.814.37.1NA2.4NANANA100NA061.9
Jung2009EA22415818.454.516.75.622.718.24.54.59.1NANANA10000NA
Kahaleh2004EA56556222.386NANANA7.13.6NA1.8NANANANANA0NA
Kang2017EA1046660.513.589.4044.231.715.417.37.7NANANANA77.95.860.638.5
Katsinelos2006EA1457.162.614.478.618.228.414.37.17.1000NANA100NA00
Kim a2013EA7256.956.48.790.37.723.7258.316.70NANANANA100NA0NA
Kim b2011EA22NANANA8627105027.313.64.5NA4.5NANANANA00
Kim c2017EA1070648100101550NA301000010NANA0NA
Klein2018EA12550.4642097.61718.5NA7.244.80.8NANANANANANA37NA
Lee a2016EA4555.656NA84.44.4NA26.715.66.72.202.2NANANANA0NA
Ma2014EA2634.627.89.938.558.384.530.819.23.8NANA15.4NANANANA34.6NA
Maguchi2003EA1258.365.721.61000NA41.725258.3NANANANANANA0NA
Napoleon2014EA9347.357NANA5.4364223.711.84.38.62.2NANANANA0100
Nguyen2010EA3652.86323.972,25.6NANA030.6NANANANANA88.911.10100
Norton2002EA285442NA46,29.513NA15.47.73.8NA9.5NANANANA00
Onkendi2014EA13052.3NA17NA32NA2914.613.10.7NANANA0.7NANA0NA
Patel2011EA384254.317.38115.817.215.87.95.302.60NANA1000055.3
Petrone2013EA145074.615.357,157.129.6NANANANANANANANANA33.373.3NA
Poincloux2014EA5657.1641696,421.42419.510.77.11.81.8NANA1.876.823.20100
Ridtitid2014EA18248.461.416.673,61519018.73.812.61.6NA3.8NA0.575.86.6039
Salmi2012EA614564NANA536111053NANANANA53160NA
Shim2014EA39616213.974,37.71571.817.910.35.1NANANA5.181.67.70100
Tsuji2015EA11565.264.516.280,9NANANA10.418.22.61.74.3NANA90.49.60NA
Van der Wiel2018EA8751.76527.77710.76025.33.412.68.11.10NANA1000071
Will2013EA5446.364.6NA79,211.8NA18.5135.61.9NANANANA44.433.3079.6
Yamamoto2018EA1776162.714.474,603040.710.220.32.82.86.8NANA93.26.80NA
Yamao2010EA3658.36614.380,63.417.9NA8.38.3002.8NANA10000100
Yoon2007EA23NANA18100NANANANANANANANANANA66.233.80NA
Zadorova2001EA1656.368NANA11.1NA14.87.47.4NANANANANA100NA0100
Amini2014SA41497417NANANANANANANANANANANA01000NA
Ceppa2013SA414056.5NA90NANA4210NANA15NANA1756120NA
Demetriades2006SA206068.513100258510000100008120100
Dixon2005SA195364.227632848.6370005052763370100
Dubois2016SA19376914NANANA68NANANANANANANA63265.3NA
Gao2016SA2159681210031.87513.6NA23.8NA14.3NANA0010000
Grobmyer2008SA29NA6320NA1016451000410143590144NA
Hong2018SA265060.2201009.17230.803.807.73.8015.588,511,50NA
Kim b2011SA21NANANANA4.71823.89.5NANANANANA9.43814,3045
Kim c2017SA2157.161151000823.8NA4.7609.54.74.7061,919029.1
Lee b2016SA185059168911.15033000236600100052.5
Mansukhani2017SA11NA56NA100934900000096436025.9
Ouaïssi2006SA265859209615867.70000110581530NA
Schneider2016SA443667NA1008.154364.3NANA3.3NA2.224.910000NA
Treitschke1999SA364159NANA042NANANANANANANANA8600100
Amini2014PD136527213NANANANANANANANANANANA01000100
Gao2016PD2252671210023.87542.8NA4.5NA9.1NANA1901000100
Lee b2016PD11946621898.311.850430407081701000NA
Stiles2018PD43455.162.91899.1NA29.4NANANANANANANANA0100019.7
Yoon2005PD675856.71895.518.258.949.3NA6016.4019.413.40100061.9
Table
Table 4. Technical specifications of endoscopic ampullectomy.
Table 4. Technical specifications of endoscopic ampullectomy.
Study 1st AuthorYearEUS PerformedPatients with EUS (%)Prior ERCPPaitents with Prior ERCP (%)Implantation of StentsSubmucosal InjectionAdditional Intervention
Ahn2013YES100YES100PDYESEA
Alvarez-Sanchez2017YES100YES100NANASurg
Bellizzi2009NO0NO0NONONA
Boix2009YESNANANANOYESAPC
Catalano2004YESNANANABD + PDNOSurg + RFA
Ceppa2013NANANANANONONA
Chang2014YES45YES100BD + PDYESSurg
Cheng2004YES29.1NANAPDYESNA
Chung2018YES52.5YES100BD + PDYESSurg + APC
De Palma2015YES25.9YES100PDNONA
Desilets2001NO0YES100BD + PDYESAPC
Dubois2016NANANANANONONA
Harano2011YES100YES100BD + PDYESEA
Hyun2017YES100NANABD + PDYESSurg
Igarashi2010YES100YES100BD + PDNOAPC
Irani2009YES42NANANANANA
Ismail2014YES19.7NANAPDNONA
Jeanniard-Malet2011YES61.9NO0BD + PDNOSurg
Jung2009NO0YES100BD + PDYESSurg
Kahaleh2004YESNANO0PDNONA
Kang2017YES38.5YES79.8BD + PDYESEA + Surg
Katsinelos2006NO0YES100BD + PDYESSurg
Kim a2013NO0NO0PDNONA
Kim b2011NANANANANANANA
Kim c2017NANANANANANANA
Klein2018YESNAYES100BD + PDYESSurg
Lee a2016YESNAYESNAPDNOEA + Surg
Ma2014NO0NANABD + PDYESEA + Surg
Maguchi2003NO0NO0BD + PDNONA
Napoleon2014YES100NO0PDYESRFA
Nguyen2010YES100NO0PDNOSurg
Norton2002NO0YES100BD + PDNOSurg
Onkendi2014YES27.8YES49.4NANANA
Patel2011YES55-3YES100PDNONA
Petrone2013NO0YES100PDNOAPC
Poincloux2014YES100YES100PDYESSurg + APC + RCT
Ridtitid2014YES39YES100PDYESCaut
Salmi2012NANANANABD + PDYESEA
Shim2014YES100YES100BD + PDYESEA+APC
Tsuji2015NO0NO0NONOSurg
Van der Wiel2018YES71YES100PDYESAPC
Will2013YES79.6YES44.8NANANA
Yamamoto2018YESNANANANONONA
Yamao2010YES100YES100BD + PDNOAPC
Yoon2007NANANANANANANA
Zadorova2001YES100YES93.6BD + PDNOAPC
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Heise, C.; Abou Ali, E.; Hasenclever, D.; Auriemma, F.; Gulla, A.; Regner, S.; Gaujoux, S.; Hollenbach, M. Systematic Review with Meta-Analysis: Endoscopic and Surgical Resection for Ampullary Lesions. J. Clin. Med. 2020, 9, 3622. https://doi.org/10.3390/jcm9113622

AMA Style

Heise C, Abou Ali E, Hasenclever D, Auriemma F, Gulla A, Regner S, Gaujoux S, Hollenbach M. Systematic Review with Meta-Analysis: Endoscopic and Surgical Resection for Ampullary Lesions. Journal of Clinical Medicine. 2020; 9(11):3622. https://doi.org/10.3390/jcm9113622

Chicago/Turabian Style

Heise, Christian, Einas Abou Ali, Dirk Hasenclever, Francesco Auriemma, Aiste Gulla, Sara Regner, Sébastien Gaujoux, and Marcus Hollenbach. 2020. "Systematic Review with Meta-Analysis: Endoscopic and Surgical Resection for Ampullary Lesions" Journal of Clinical Medicine 9, no. 11: 3622. https://doi.org/10.3390/jcm9113622

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop